IDH1 and acute myeloid leukemia: There are several other clinical trials for ivosidenib that include a phase I trial to investigate efficacy and safety of ivosidenib in combination with fludarabine, cytarabine, and G-CSF (FLAG) chemotherapy in R/R AML and MDS patients with IDH1 mutations (NCT04250051).